Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441022 | 0.85 | DGAT1 (0.42) | DGAT1GRM5GRM1 | |
| SCHEMBL438191 | 0.84 | DGAT1 (0.51) | DGAT1ABHD6DAGLALMNA | |
| SCHEMBL440613 | 0.84 | DGAT1 (0.44) | DGAT1 | |
| SCHEMBL440674 | 0.84 | DGAT1 (0.44) | DGAT1TACR1GRM5GRM1 | |
| SCHEMBL438968 | 0.83 | USP30 (0.44) | DGAT1LMNAGRM5GRM1 | |
| SCHEMBL440362 | 0.82 | DGAT1 (0.43) | DGAT1LMNATACR1 | |
| SCHEMBL438606 | 0.82 | DGAT1 (0.45) | DGAT1LMNA | |
| SCHEMBL437429 | 0.79 | DGAT1 (0.44) | DGAT1TACR1GRM5GRM1 | |
| SCHEMBL440132 | 0.77 | DGAT1 (0.42) | DGAT1LMNA | |
| SCHEMBL439794 | 0.76 | DGAT1 (0.52) | DGAT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885ABHD6 87/4885DAGLA 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.